Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973145140> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W1973145140 endingPage "A16" @default.
- W1973145140 startingPage "A16" @default.
- W1973145140 abstract "Rofecoxib and celecoxib, the first selective COX-2 inhibitors introduced into the marketplace, have recognized mechanism-based renovascular effects similar to those associated with the non-selective NSAIDs which are dual COX-1 and COX-2 inhibitors. Specifically, edema, blood pressure elevation, attenuation of the effects of anti-hypertensive agents, and acute renal failure were manifest in a small percentage of patients. To assess the renovascular safety of etoricoxib, a new highly selective COX-2 inhibitor. The etoricoxib development program contains information on 3348 patients participating in 8 phase III studies in osteoarthritis, rheumatoid arthritis, chronic low back pain, and surveillance endoscopy. Grouped together, the patients in these studies represent 1491 placebo, 658 etoricoxib 60 mg/day, 889 etoricoxib 90 mg/day, 472 etoricoxib 120 mg/day, 1034 naproxen 1000mg/day, 226 ibuprofen 2400 mg/day treated patients. As part of the program-wide safety survey, lower extremity edema adverse experiences (AEs) and hypertension AEs, as well as discontinuations due to these AEs were analyzed. The overall incidence of lower extremity edema occurred in 28 (1.9%), 21 (3.2%), 13 (1.5%), 6 (1.3%), 24 (2.3%), and 4 (1.8%) of patients in the placebo, 60, 90, 120-mg etoricoxib, naproxen, and ibuprofen groups, respectively. Discontinuations due to lower extremity edema were infrequent in all active treatment groups; in 3 (0.3%), 2 (0.3%), 1 (0.1%), 0 (0.0%), 0 (0.0%), and 1 (0.4%) of patients in the placebo, 60, 90, 120-mg etoricoxib, naproxen, and ibuprofen groups, respectively. Hypertension occurred in 30 (2.0%), 26 (4.0%), 30 (3.4%), 22 (4.7%), 30 (2.9%), and 15 (6.6%) of patients in the placebo, 60, 90, 120-mg etoricoxib, naproxen, and ibuprofen groups, respectively. Few patients discontinued due to hypertension: 0(0.0%), 1(0.2%), 2(0.2%), 2(0.4%), 1(0.1%), and 0 (0.0%) of patients in the placebo, 60, 90, 120-mg etoricoxib, naproxen, and ibuprofen groups, respectively. There were no incidences of acute renal failure in any treatment group. Based on this combined data review, the risk of lower extremity edema and hypertension AEs with etoricoxib was low and generally similar to comparator NSAIDs. There was no compelling evidence of dose-related trends for these AEs with the various etoricoxib doses studied." @default.
- W1973145140 created "2016-06-24" @default.
- W1973145140 creator A5003004918 @default.
- W1973145140 creator A5011873042 @default.
- W1973145140 creator A5012598657 @default.
- W1973145140 creator A5015406504 @default.
- W1973145140 creator A5071063211 @default.
- W1973145140 creator A5088953706 @default.
- W1973145140 date "2002-04-01" @default.
- W1973145140 modified "2023-10-17" @default.
- W1973145140 title "Renovascular safety profile of etoricoxib" @default.
- W1973145140 doi "https://doi.org/10.1016/s0895-7061(02)02315-4" @default.
- W1973145140 hasPublicationYear "2002" @default.
- W1973145140 type Work @default.
- W1973145140 sameAs 1973145140 @default.
- W1973145140 citedByCount "1" @default.
- W1973145140 countsByYear W19731451402023 @default.
- W1973145140 crossrefType "journal-article" @default.
- W1973145140 hasAuthorship W1973145140A5003004918 @default.
- W1973145140 hasAuthorship W1973145140A5011873042 @default.
- W1973145140 hasAuthorship W1973145140A5012598657 @default.
- W1973145140 hasAuthorship W1973145140A5015406504 @default.
- W1973145140 hasAuthorship W1973145140A5071063211 @default.
- W1973145140 hasAuthorship W1973145140A5088953706 @default.
- W1973145140 hasBestOaLocation W19731451401 @default.
- W1973145140 hasConcept C126322002 @default.
- W1973145140 hasConcept C142724271 @default.
- W1973145140 hasConcept C181199279 @default.
- W1973145140 hasConcept C185592680 @default.
- W1973145140 hasConcept C197934379 @default.
- W1973145140 hasConcept C204787440 @default.
- W1973145140 hasConcept C27081682 @default.
- W1973145140 hasConcept C2776214540 @default.
- W1973145140 hasConcept C2776467144 @default.
- W1973145140 hasConcept C2777575956 @default.
- W1973145140 hasConcept C2778115740 @default.
- W1973145140 hasConcept C2778582115 @default.
- W1973145140 hasConcept C2779689624 @default.
- W1973145140 hasConcept C2779944601 @default.
- W1973145140 hasConcept C2780886150 @default.
- W1973145140 hasConcept C42219234 @default.
- W1973145140 hasConcept C55493867 @default.
- W1973145140 hasConcept C71924100 @default.
- W1973145140 hasConcept C98274493 @default.
- W1973145140 hasConceptScore W1973145140C126322002 @default.
- W1973145140 hasConceptScore W1973145140C142724271 @default.
- W1973145140 hasConceptScore W1973145140C181199279 @default.
- W1973145140 hasConceptScore W1973145140C185592680 @default.
- W1973145140 hasConceptScore W1973145140C197934379 @default.
- W1973145140 hasConceptScore W1973145140C204787440 @default.
- W1973145140 hasConceptScore W1973145140C27081682 @default.
- W1973145140 hasConceptScore W1973145140C2776214540 @default.
- W1973145140 hasConceptScore W1973145140C2776467144 @default.
- W1973145140 hasConceptScore W1973145140C2777575956 @default.
- W1973145140 hasConceptScore W1973145140C2778115740 @default.
- W1973145140 hasConceptScore W1973145140C2778582115 @default.
- W1973145140 hasConceptScore W1973145140C2779689624 @default.
- W1973145140 hasConceptScore W1973145140C2779944601 @default.
- W1973145140 hasConceptScore W1973145140C2780886150 @default.
- W1973145140 hasConceptScore W1973145140C42219234 @default.
- W1973145140 hasConceptScore W1973145140C55493867 @default.
- W1973145140 hasConceptScore W1973145140C71924100 @default.
- W1973145140 hasConceptScore W1973145140C98274493 @default.
- W1973145140 hasIssue "4" @default.
- W1973145140 hasLocation W19731451401 @default.
- W1973145140 hasOpenAccess W1973145140 @default.
- W1973145140 hasPrimaryLocation W19731451401 @default.
- W1973145140 hasRelatedWork W1562063526 @default.
- W1973145140 hasRelatedWork W1619221657 @default.
- W1973145140 hasRelatedWork W1785305858 @default.
- W1973145140 hasRelatedWork W1984082177 @default.
- W1973145140 hasRelatedWork W1993961357 @default.
- W1973145140 hasRelatedWork W2010818945 @default.
- W1973145140 hasRelatedWork W2339905124 @default.
- W1973145140 hasRelatedWork W2418824387 @default.
- W1973145140 hasRelatedWork W324740501 @default.
- W1973145140 hasRelatedWork W4367281797 @default.
- W1973145140 hasVolume "15" @default.
- W1973145140 isParatext "false" @default.
- W1973145140 isRetracted "false" @default.
- W1973145140 magId "1973145140" @default.
- W1973145140 workType "article" @default.